204 related articles for article (PubMed ID: 33727829)
21. Polymerase ɛ (POLE) mutations in endometrial cancer: clinical outcomes and implications for Lynch syndrome testing.
Billingsley CC; Cohn DE; Mutch DG; Stephens JA; Suarez AA; Goodfellow PJ
Cancer; 2015 Feb; 121(3):386-94. PubMed ID: 25224212
[TBL] [Abstract][Full Text] [Related]
22. Durable responses to immunotherapy of non-small cell lung cancers harboring MET exon-14-skipping mutation: A series of 6 cases.
Mayenga M; Assié JB; Monnet I; Massiani MA; Tabeze L; Friard S; Fraboulet S; Métivier AC; Chouaïd C; Zemoura L; Longchampt E; Callens C; Melaabi S; Couderc LJ; Doubre H
Lung Cancer; 2020 Dec; 150():21-25. PubMed ID: 33045465
[TBL] [Abstract][Full Text] [Related]
23. Clinicopathological characteristics of POLE mutation in patients with non-small-cell lung cancer.
Song Z; Cheng G; Xu C; Wang W; Shao Y; Zhang Y
Lung Cancer; 2018 Apr; 118():57-61. PubMed ID: 29572003
[TBL] [Abstract][Full Text] [Related]
24. Exceptional Response of Cryoablation Followed by Pembrolizumab in a Patient with Metastatic Cervical Carcinosarcoma with High Tumor Mutational Burden: A Case Report.
Zhu B; Liu Y; Li J; Diao L; Shao L; Han-Zhang H; Zhang L; Kang Q; Yang W
Oncologist; 2020 Jan; 25(1):15-18. PubMed ID: 31848313
[TBL] [Abstract][Full Text] [Related]
25. Circulating Tumor DNA Response and Minimal Residual Disease Assessment in DNA Polymerase Epsilon-Mutated Colorectal Cancer Undergoing Immunotherapy.
Lutfi A; Afghan MK; Kasi PM
Cureus; 2023 Aug; 15(8):e43391. PubMed ID: 37593074
[TBL] [Abstract][Full Text] [Related]
26. Upfront progression under pembrolizumab followed by a complete response after encorafenib and cetuximab treatment in BRAF V600E-mutated and microsatellite unstable metastatic colorectal cancer patient: A case report.
Gallois C; Taieb J; Sabouret A; Broudin C; Karoui M; Garinet S; Zaanan A
Genes Chromosomes Cancer; 2022 Feb; 61(2):114-118. PubMed ID: 34773327
[TBL] [Abstract][Full Text] [Related]
27. Dramatic Response to Pembrolizumab Monotherapy in a Patient With ARID1A-Mutant Lung Adenocarcinoma: Case Report.
Harada G; Amano MT; Antonacio FF; Behar MH; Nabuco-de-Araujo PHX; Buchpiguel CA; Junior GC
Clin Lung Cancer; 2021 Sep; 22(5):e708-e711. PubMed ID: 33658161
[TBL] [Abstract][Full Text] [Related]
28. Complete response to pembrolizumab in a patient with metastatic colon cancer with microsatellite instability and a history of Guillain-Barre syndrome.
Wang C; Sandhu J; Fakih M
J Gastrointest Oncol; 2019 Feb; 10(1):161-165. PubMed ID: 30788172
[TBL] [Abstract][Full Text] [Related]
29. Subunits of ARID1 serve as novel biomarkers for the sensitivity to immune checkpoint inhibitors and prognosis of advanced non-small cell lung cancer.
Sun D; Tian L; Zhu Y; Wo Y; Liu Q; Liu S; Li H; Hou H
Mol Med; 2020 Aug; 26(1):78. PubMed ID: 32791957
[TBL] [Abstract][Full Text] [Related]
30. Tumor molecular profiling of responders and non-responders following pembrolizumab monotherapy in chemotherapy resistant advanced cervical cancer.
Ngoi NYL; Heong V; Lee XW; Huang YQ; Thian YL; Choo BA; Lim D; Lim YW; Lim SE; Ilancheran A; Soong R; Tan DSP
Gynecol Oncol Rep; 2018 May; 24():1-5. PubMed ID: 29892689
[TBL] [Abstract][Full Text] [Related]
31. Somatic mutations in genes associated with mismatch repair predict survival in patients with metastatic cancer receiving immune checkpoint inhibitors.
Liu Y; Chen L; Zhang S; Shu Y; Qi Q; Zhu M; Peng Y; Ling Y
Oncol Lett; 2020 Oct; 20(4):27. PubMed ID: 32774500
[TBL] [Abstract][Full Text] [Related]
32. Excellent Response to Atezolizumab After Clinically Defined Hyperprogression Upon Previous Treatment With Pembrolizumab in Metastatic Triple-Negative Breast Cancer: A Case Report and Review of the Literature.
Feng D; Guan Y; Liu M; He S; Zhao W; Yin B; Liang J; Li Y; Wang J
Front Immunol; 2021; 12():608292. PubMed ID: 34135884
[TBL] [Abstract][Full Text] [Related]
33. Distinctive genomic characteristics in
He J; Ouyang W; Zhao W; Shao L; Li B; Liu B; Wang D; Han-Zhang H; Zhang Z; Shao L; Li W
Ann Transl Med; 2021 Jan; 9(2):129. PubMed ID: 33569431
[TBL] [Abstract][Full Text] [Related]
34. Four-Year Disease-Free Remission in a Patient With POLE Mutation-Associated Colorectal Cancer Treated Using Anti-PD-1 Therapy.
Durando ML; Menghani SV; Baumann JL; Robles DG; Day TA; Vaziri C; Scott AJ
J Natl Compr Canc Netw; 2022 Mar; 20(3):218-223. PubMed ID: 35276675
[TBL] [Abstract][Full Text] [Related]
35. Mutation spectrum of POLE and POLD1 mutations in South East Asian women presenting with grade 3 endometrioid endometrial carcinomas.
Wong A; Kuick CH; Wong WL; Tham JM; Mansor S; Loh E; Jain S; Vikas NN; Tan SH; Chan SH; Li ST; Chew SH; Hong W; Ngeow J
Gynecol Oncol; 2016 Apr; 141(1):113-20. PubMed ID: 26748215
[TBL] [Abstract][Full Text] [Related]
36. Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab.
Dall'Olio FG; Calabrò D; Conci N; Argalia G; Marchese PV; Fabbri F; Fragomeno B; Ricci D; Fanti S; Ambrosini V; Ardizzoni A
Eur J Cancer; 2021 Jun; 150():99-107. PubMed ID: 33892411
[TBL] [Abstract][Full Text] [Related]
37. Tumor Mutational Burden Guides Therapy in a Treatment Refractory
Bhangoo MS; Boasberg P; Mehta P; Elvin JA; Ali SM; Wu W; Klempner SJ
Oncologist; 2018 May; 23(5):518-523. PubMed ID: 29386312
[TBL] [Abstract][Full Text] [Related]
38. POLE gene hotspot mutations in advanced pancreatic cancer.
Guenther M; Veninga V; Kumbrink J; Haas M; Westphalen CB; Kruger S; Heinemann V; Kirchner T; Boeck S; Jung A; Ormanns S
J Cancer Res Clin Oncol; 2018 Nov; 144(11):2161-2166. PubMed ID: 30194485
[TBL] [Abstract][Full Text] [Related]
39. Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.
Wong JSL; Kwok GGW; Tang V; Li BCW; Leung R; Chiu J; Ma KW; She WH; Tsang J; Lo CM; Cheung TT; Yau T
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33563773
[TBL] [Abstract][Full Text] [Related]
40. Durable Complete Response to Pembrolizumab in Esophageal Squamous Cell Carcinoma With Divergent Microsatellite Status: A Case Report.
Zeng T; Zhang L; Chen C; Zhao X; Liu X; Ran F; Yong T; Yang Y; Zhang H; Zhang Y
Front Oncol; 2021; 11():767957. PubMed ID: 34868995
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
